MedImmune Ventures, the corporate venturing unit of AstraZeneca, has helped Coferon, a US-based healthcare company, raise $12m. The unit was joined in Coferon’s series B by venture firms Hatteras Venture Partners and Ascent Biomedical Ventures. Dr. Colin Goddard, who had been acting as a part-time executive chairman for Coferon and was formerly chief executive of…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
